DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the PE ratio of Ishita Drugs & Industries Ltd?

Ishita Drugs & Industries Ltd has a price-to-earnings (PE) ratio of 27.7 in the Healthcare sector.

What is the market capitalisation of Ishita Drugs & Industries Ltd?

Ishita Drugs & Industries Ltd has a market capitalisation of approximately ₹22 crore.

Ishita Drugs & Industries Ltd

ISHITADRUGSINDUSLTD·NSE·Healthcare

₹0.00▲ +0.00 (+0.00%)

⚠️Trading suspended. Not a live price.

Healthcare · Pharmaceuticals

A steady, established business

52W₹66

₹91-266%

Open

—

High

—

Low

—

Prev Close

—

Volume

—

VWAP

—

Snapshot

Key fundamentals

Market Cap

₹22 Cr

P/E Ratio

27.70Fair

P/B Ratio

1.86

EPS

₹2.91

Book Value

₹38.70

ROE

6.98%Weak

ROCE

9.91%Weak

Dividend Yield

0.00%

Debt / Equity

0.01Low

Face Value

₹10.00

52W High

₹90.85

52W Low

₹66.00

Sector

Healthcare

Industry

Pharmaceuticals

Fairly Valued

None moatMedium uncertainty

Fair value estimate

₹39

No recent traded price

BearFair valueBull

₹33₹39₹47

/100

Business quality — Watch the fundamentals

Growth 50Profitability 16Efficiency 10Valuation 78

Plain English

Our view

A steady, established business
Virtually debt-free balance sheet
Weak returns on equity (7%)

Strengths

Virtually debt-free balance sheet
Promoters hold a controlling stake

Risks

Weak returns on equity (7%)

How we got there

Fair value methods

Residual income

8% ROE fading to 12% over ~3 yrs, on ₹39 book

₹37

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹47

Analyst target

No analyst coverage

—

Blended fair value₹39

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Promoters hold a controlling stake

Bear case

Weak returns on equity (7%)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

27.7Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

7.0%Weak

Above 15% is considered healthy for Indian equities

ROCE

9.9%Weak

Above 18% means capital is working hard

Debt/Eq

0.01Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹22 Cr

P/B

1.86

EPS

₹2.91

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Reasonable

P/E 27.7×

Growth

Steady

+7% rev CAGR

Profitability

Modest

7.0% ROE

Financial health

Rock solid

D/E 0.01

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+6.7%

+1.0%

10Y

+7.5%

Profit

+10.4%

-1.2%

10Y

+18.7%

EPS

+8.8%

-2.1%

10Y

+18.2%

Profile

Pros

Company has reduced debt.
Company is almost debt free.

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
The company has delivered a poor sales growth of 1.00% over past five years.
Company has a low return on equity of 7.72% over last 3 years.
Earnings include an other income of Rs.0.47 Cr.
Working capital days have increased from 65.9 days to 146 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

50%

Promoter

Promoters

50.0%0.00

Public

47.4%+1.04

FII / FPI

0.0%0.00

DII

0.0%0.00

Others

2.6%

Total shareholders

5,194-69 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter50.04%

Public47.37%

Others2.59%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1992, Ishita Drugs & Industries Ltd is engaged in the manufacturing of various APIs and drug intermediates[1]